Search clinical trials for: Bimatoprost (Lumigan)

Total 199 results

Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Canada
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Completed

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Allergan

Completed

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Idiopathic Eyelash Hypotrichosis

Russian Federation, Sweden, United States, United Kingdom
Kenneth Beer
Allergan

Completed

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Hypotrichosis

United States
Allergan

Completed

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Androgenetic Alopecia

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Alopecia | Baldness

United States, Germany
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Allergan

Completed

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Eyebrow Hypotrichosis

United States, Canada
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
Allergan

Completed

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Glaucoma | Open-Angle Ocular Hypertension

Spain, United States, Singapore, Australia, Denmark, France, Poland, Russian Federation, Thailand
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States, Germany
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Allergan

Completed

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Netherlands
Allergan

Completed

A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Germany
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension

United States
Laboratoires Thea

Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Healthy Volunteers

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
AbbVie

Completed

Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

United States, Australia, Canada, Denmark, France, Germany, Israel, New Zealand, Philippines, Russian Federation, United Kingdom, Poland
Johns Hopkins University

Recruiting

Bimatoprost as a Treatment for Graves' Orbitopathy

Graves Ophthalmopathy

United States
Allergan

Completed

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Eyelash Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

Eyelash Hypotrichosis

Korea, Republic of
ForSight Vision5, Inc.

Completed

Bimatoprost Ocular Insert Pharmacokinetic Study

Healthy Volunteers

United States
Indiana University School of Medicine

Completed

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

Cataract

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
AbbVie

Enrolling by invitation

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, Italy, Korea, Republic of, New Zealand, Peru, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Thailan... and more
Innovative Medical

Completed

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Glaucoma

United States
Allergan

Completed

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Ocular Hypertension | Glaucoma, Open-Angle

Canada
AbbVie

Available

Expanded Access to Bimatoprost (Durysta)

Open-angle Glaucoma
Allergan

Completed

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Ocular Hypertension | Glaucoma

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

Ocular Hypertension Glaucoma

Bulgaria
Innovative Medical

Completed

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Glaucoma

United States
Julie Dawson

Completed

RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. (CMO)

Open Angle Glaucoma and Cataract

United Kingdom
Allergan

Completed

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Eyelash Hypotrichosis

Japan
Jonsson Comprehensive Cancer Center

Withdrawn

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Breast Cancer | Alopecia

United States
Allergan

Completed

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Wake Forest University Health Sciences

Recruiting

Improving Disease Severity

Psoriasis | Alopecia Areata | Polymorphous Light Eruption

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

Hypotrichosis

United States, United Kingdom
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Allergan

Completed

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Hypotrichosis

United States

3

Subscribe